{"id":31781,"date":"2023-10-19T09:09:50","date_gmt":"2023-10-19T09:09:50","guid":{"rendered":"https:\/\/innodebt.com\/investing\/nestle-works-on-new-range-of-weight-loss-drug-companion-products-as-sales-miss-estimates\/"},"modified":"2023-10-19T09:09:51","modified_gmt":"2023-10-19T09:09:51","slug":"nestle-works-on-new-range-of-weight-loss-drug-companion-products-as-sales-miss-estimates","status":"publish","type":"post","link":"https:\/\/innodebt.com\/?p=31781","title":{"rendered":"Nestle works on new range of weight-loss drug companion products as sales miss estimates"},"content":{"rendered":"
\n

Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range of goods to \u201cserve as companion products\u201d to weight-loss drugs that pose a threat to the confectionary company\u2019s revenue.<\/p>\n

The Swiss multinational told investors its revenues had dropped 0.4% year-on-year, to \u20a368.83 billion ($76.59 billion) in the first nine months of 2023, due to unfavorable currency exchange rates and divestments.\u00a0<\/p>\n

\n

The sales figures saw Nestle miss analysts\u2019 estimates by 1% with a selection of 20 analysts polled by the Kit Kat seller itself having previously forecast the firm would generate sales worth \u20a369.54 billion.\u00a0<\/p>\n

Nestle shares
\n NESN,
\n -2.21%<\/bg-quote>
\n fell 2%. The stock has dropped 7% this year.<\/p>\n

Foreign exchange rates caused Nestle\u2019s sales to drop 7.4% as the firm\u2019s decision to sell its Gerber Good Start baby milk formula brand and close its New York City-based food delivery business Freshly led to a 0.4% drop in revenues.\u00a0<\/p>\n

Meanwhile, the Nescafe maker reported organic growth of 7.8%, driven by an 8.4% hike in prices across its business. Company CEO Mark Schneider said the price hikes helped Nestle \u201cnavigate historic inflation levels.\u201d\u00a0<\/p>\n

However, Nestle\u2019s organic growth rate also underwhelmed, with analysts having previously forecast the firm would post organic growth of 8.5%, according to 20 analysts polled by Nestle.\u00a0\u00a0<\/p>\n

Nestle\u2019s Schneider brushed aside any impact of weight-loss drugs on the company\u2019s business so far, as he said the appetite-suppressing medicines will have little impact on sales of coffee and pet food, which account for almost half of revenues.\u00a0\u00a0<\/p>\n

Schneider, however, told the media that the company is planning to launch a new range of products marketed towards users of weight-loss drugs such as Ozempic, according to Reuters. The announcement follows news Novo Nordisk\u2019s
\n NVO,
\n -0.58%<\/bg-quote>
\n new drug saw the Danish pharma company overtake Nestle as Europe\u2019s most valuable by market cap.\u00a0<\/p>\n

Nestle\u2019s underwhelming results follow news the company is planning to shut down its baby milk factory in Limerick, Ireland, by the first quarter of 2026, due to slower demand caused by lower birth rates in China, in a move that will lead to the loss of 542 jobs.\u00a0<\/p>\n

The company on Thursday also said it has \u201ctemporarily shut down\u201d a production facility in Israel in response to the conflict that has engulfed the country in recent weeks, according to Reuters.\u00a0<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range of goods to \u201cserve as companion products\u201d to weight-loss drugs that pose a threat to the confectionary company\u2019s revenue. The Swiss multinational told investors its revenues had dropped […]<\/p>\n","protected":false},"author":1,"featured_media":31782,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[32],"tags":[],"class_list":{"0":"post-31781","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"yoast_head":"\nNestle works on new range of weight-loss drug companion products as sales miss estimates | Innodebt<\/title>\n<meta name=\"description\" content=\"Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/innodebt.com\/?p=31781\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nestle works on new range of weight-loss drug companion products as sales miss estimates | Innodebt\" \/>\n<meta property=\"og:description\" content=\"Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range\" \/>\n<meta property=\"og:url\" content=\"https:\/\/innodebt.com\/?p=31781\" \/>\n<meta property=\"og:site_name\" content=\"Innodebt\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-19T09:09:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-19T09:09:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/10\/1697706590_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/innodebt.com\/?p=31781#article\",\"isPartOf\":{\"@id\":\"https:\/\/innodebt.com\/?p=31781\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/innodebt.com\/#\/schema\/person\/742362d9a293429cc45829acf21919b4\"},\"headline\":\"Nestle works on new range of weight-loss drug companion products as sales miss estimates\",\"datePublished\":\"2023-10-19T09:09:50+00:00\",\"dateModified\":\"2023-10-19T09:09:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/innodebt.com\/?p=31781\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/innodebt.com\/#organization\"},\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/innodebt.com\/?p=31781#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/innodebt.com\/?p=31781\",\"url\":\"https:\/\/innodebt.com\/?p=31781\",\"name\":\"Nestle works on new range of weight-loss drug companion products as sales miss estimates | Innodebt\",\"isPartOf\":{\"@id\":\"https:\/\/innodebt.com\/#website\"},\"datePublished\":\"2023-10-19T09:09:50+00:00\",\"dateModified\":\"2023-10-19T09:09:51+00:00\",\"description\":\"Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range\",\"breadcrumb\":{\"@id\":\"https:\/\/innodebt.com\/?p=31781#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/innodebt.com\/?p=31781\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/innodebt.com\/?p=31781#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/innodebt.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nestle works on new range of weight-loss drug companion products as sales miss estimates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/innodebt.com\/#website\",\"url\":\"https:\/\/innodebt.com\/\",\"name\":\"Funding Factories\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/innodebt.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/innodebt.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/innodebt.com\/#organization\",\"name\":\"Funding Factories\",\"url\":\"https:\/\/innodebt.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/innodebt.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"contentUrl\":\"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"width\":780,\"height\":140,\"caption\":\"Funding Factories\"},\"image\":{\"@id\":\"https:\/\/innodebt.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/innodebt.com\/#\/schema\/person\/742362d9a293429cc45829acf21919b4\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/innodebt.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"contentUrl\":\"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/innodebt.com\"],\"url\":\"https:\/\/innodebt.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nestle works on new range of weight-loss drug companion products as sales miss estimates | Innodebt","description":"Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/innodebt.com\/?p=31781","og_locale":"en_US","og_type":"article","og_title":"Nestle works on new range of weight-loss drug companion products as sales miss estimates | Innodebt","og_description":"Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range","og_url":"https:\/\/innodebt.com\/?p=31781","og_site_name":"Innodebt","article_published_time":"2023-10-19T09:09:50+00:00","article_modified_time":"2023-10-19T09:09:51+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/10\/1697706590_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/innodebt.com\/?p=31781#article","isPartOf":{"@id":"https:\/\/innodebt.com\/?p=31781"},"author":{"name":"News Room","@id":"https:\/\/innodebt.com\/#\/schema\/person\/742362d9a293429cc45829acf21919b4"},"headline":"Nestle works on new range of weight-loss drug companion products as sales miss estimates","datePublished":"2023-10-19T09:09:50+00:00","dateModified":"2023-10-19T09:09:51+00:00","mainEntityOfPage":{"@id":"https:\/\/innodebt.com\/?p=31781"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/innodebt.com\/#organization"},"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/innodebt.com\/?p=31781#respond"]}]},{"@type":"WebPage","@id":"https:\/\/innodebt.com\/?p=31781","url":"https:\/\/innodebt.com\/?p=31781","name":"Nestle works on new range of weight-loss drug companion products as sales miss estimates | Innodebt","isPartOf":{"@id":"https:\/\/innodebt.com\/#website"},"datePublished":"2023-10-19T09:09:50+00:00","dateModified":"2023-10-19T09:09:51+00:00","description":"Nestle on Thursday posted worse-than-expected results for the first nine months of 2023 as the company\u2019s CEO said the firm is now working on a new range","breadcrumb":{"@id":"https:\/\/innodebt.com\/?p=31781#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/innodebt.com\/?p=31781"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/innodebt.com\/?p=31781#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/innodebt.com\/"},{"@type":"ListItem","position":2,"name":"Nestle works on new range of weight-loss drug companion products as sales miss estimates"}]},{"@type":"WebSite","@id":"https:\/\/innodebt.com\/#website","url":"https:\/\/innodebt.com\/","name":"Funding Factories","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/innodebt.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/innodebt.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/innodebt.com\/#organization","name":"Funding Factories","url":"https:\/\/innodebt.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/innodebt.com\/#\/schema\/logo\/image\/","url":"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","contentUrl":"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","width":780,"height":140,"caption":"Funding Factories"},"image":{"@id":"https:\/\/innodebt.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/innodebt.com\/#\/schema\/person\/742362d9a293429cc45829acf21919b4","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/innodebt.com\/#\/schema\/person\/image\/","url":"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","contentUrl":"https:\/\/innodebt.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","caption":"News Room"},"sameAs":["https:\/\/innodebt.com"],"url":"https:\/\/innodebt.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/innodebt.com\/index.php?rest_route=\/wp\/v2\/posts\/31781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/innodebt.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/innodebt.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/innodebt.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/innodebt.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31781"}],"version-history":[{"count":1,"href":"https:\/\/innodebt.com\/index.php?rest_route=\/wp\/v2\/posts\/31781\/revisions"}],"predecessor-version":[{"id":31783,"href":"https:\/\/innodebt.com\/index.php?rest_route=\/wp\/v2\/posts\/31781\/revisions\/31783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/innodebt.com\/index.php?rest_route=\/wp\/v2\/media\/31782"}],"wp:attachment":[{"href":"https:\/\/innodebt.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/innodebt.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/innodebt.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}